1. Optimizing the Immunogenicity of HIV Vaccines by Adjuvants - NIAID Workshop Report.
- Author
-
Singh A, Boggiano C, Eller MA, Maciel M Jr, Marovich MA, Mehra VL, Mo AX, Singleton KL, and Leitner WW
- Subjects
- Humans, Adjuvants, Immunologic, National Institute of Allergy and Infectious Diseases (U.S.), National Institutes of Health (U.S.), United States, AIDS Vaccines, HIV Infections prevention & control
- Abstract
This report summarizes the highlights of a workshop convened by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), on April 4-5, 2022, to provide a discussion forum for sharing insights on the current status, key challenges, and next steps to advance the current landscape of promising adjuvants in preclinical and clinical human immunodeficiency virus (HIV) vaccine studies. A key goal was to solicit and share recommendations on scientific, regulatory, and operational guidelines for bridging the gaps in rational selection, access, and formulation of clinically relevant adjuvants for HIV vaccine candidates. The NIAID Vaccine Adjuvant Program working group remains committed to accentuate promising adjuvants and nurturing collaborations between adjuvant and HIV vaccine developers., (Copyright © 2023.)
- Published
- 2023
- Full Text
- View/download PDF